9 VCs and 1 funds investing in B2B Technology
Managing General Partner
Noro-Moseley Partners
Check: $5M-$20M target investment range published by Noro-Moseley Partners; no person-specific range is disclosed.
Allen Moseley is part of Noro-Moseley Partners's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Invest early growth capital in rapidly scaling B2B technology and healthcare companies with strong economics, meaningful revenue, and limited prior funding.
General Partner
Noro-Moseley Partners
Check: $5M-$20M target investment range published by Noro-Moseley Partners; no person-specific range is disclosed.
Alan Taetle is part of Noro-Moseley Partners's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Invest early growth capital in rapidly scaling B2B technology and healthcare companies with strong economics, meaningful revenue, and limited prior funding.
General Partner
Noro-Moseley Partners
Check: $5M-$20M target investment range published by Noro-Moseley Partners; no person-specific range is disclosed.
Spence McClelland is part of Noro-Moseley Partners's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Invest early growth capital in rapidly scaling B2B technology and healthcare companies with strong economics, meaningful revenue, and limited prior funding.
General Partner
Noro-Moseley Partners
Check: $5M-$20M target investment range published by Noro-Moseley Partners; no person-specific range is disclosed.
Vasant Kamath is part of Noro-Moseley Partners's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Invest early growth capital in rapidly scaling B2B technology and healthcare companies with strong economics, meaningful revenue, and limited prior funding.
Principal
Noro-Moseley Partners
Check: $5M-$20M target investment range published by Noro-Moseley Partners; no person-specific range is disclosed.
Ryan Collins is part of Noro-Moseley Partners's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Invest early growth capital in rapidly scaling B2B technology and healthcare companies with strong economics, meaningful revenue, and limited prior funding.
Administrative Partner, CFO
Noro-Moseley Partners
Check: $5M-$20M target investment range published by Noro-Moseley Partners; no person-specific range is disclosed.
Bill Hudson is part of Noro-Moseley Partners's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Invest early growth capital in rapidly scaling B2B technology and healthcare companies with strong economics, meaningful revenue, and limited prior funding.
Senior Associate
Noro-Moseley Partners
Check: $5M-$20M target investment range published by Noro-Moseley Partners; no person-specific range is disclosed.
Thomas Collier is part of Noro-Moseley Partners's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Invest early growth capital in rapidly scaling B2B technology and healthcare companies with strong economics, meaningful revenue, and limited prior funding.
Associate
Noro-Moseley Partners
Check: $5M-$20M target investment range published by Noro-Moseley Partners; no person-specific range is disclosed.
Brandon Aponte is part of Noro-Moseley Partners's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Invest early growth capital in rapidly scaling B2B technology and healthcare companies with strong economics, meaningful revenue, and limited prior funding.
Executive Assistant and Office Manager
Noro-Moseley Partners
Check: $5M-$20M target investment range published by Noro-Moseley Partners; no person-specific range is disclosed.
Missy Evans is part of Noro-Moseley Partners's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Invest early growth capital in rapidly scaling B2B technology and healthcare companies with strong economics, meaningful revenue, and limited prior funding.